Treatment administration
Patients were randomly assigned to one of four treatment arms: Arm 1: zolbetuximab Q3W + ZA (4 mg); Arm 2: zolbetuximab Q3W + ZA (4 mg) + low-dose IL-2 (1 mIU); Arm 3: zolbetuximab Q3W + ZA (4 mg) + intermediate-dose IL-2 (3 mIU); Arm 4: zolbetuximab Q3W. In all treatment arms, zolbetuximab was administered as a 2-h IV infusion at a dose of 800 mg/m